Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but These are uncommon in this malignancy when compared with other lymphoid neoplasms. CHD2 Unfit sufferers even have the alternative of venetoclax moreover obinutuzumab (VO) as frontline therapy. This is